(News Bulletin 247) – Bayer announces that its wholly owned and independent subsidiary, BlueRock Therapeutics LP, will work with Rune Labs and Emerald Innovations, specialists in wearable and invisible contactless digital health technologies, to improve monitoring and collecting data on Parkinson’s disease in clinical trials.
Currently, monitoring and data collection in clinical trials for Parkinson’s disease combine subjective patient reporting tools such as diaries and questionnaires with periodic neurological and mobility assessments in a clinical setting that capture only a specific moment in time.
This approach does not provide a complete, real-time picture of disease progression and the impact of a patient’s daily experience with Parkinson’s symptoms.
“New tools and approaches are needed to ease the burden of patient reporting in trials and to more effectively measure and assess disease progression,” commented Seth Ettenberg, president and CEO of BlueRock Therapeutics.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
